NCT01328821View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

April 30, 2011

Study Completion Date

June 30, 2011

Conditions
Diabetic Nephropathy
Interventions
DRUG

CTP-499

600 mg, 1200 mg, 1800 mg and 2400 mg

DRUG

CTP-499

400 mg immediate release capsule

Trial Locations (1)

07601

Frontage, Hackensack

Sponsors
All Listed Sponsors
lead

Concert Pharmaceuticals

INDUSTRY